Reprint

Novel Natural-based Biomolecules Discovery for Tackling Chronic Diseases

Edited by
March 2021
180 pages
  • ISBN978-3-0365-0386-8 (Hardback)
  • ISBN978-3-0365-0387-5 (PDF)

This book is a reprint of the Special Issue Novel Natural-based Biomolecules Discovery for Tackling Chronic Diseases that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary
Natural-based biomolecules continuously play an important role in novel drug discovery for the treatment of chronic diseases. The development of natural peptide/protein-based, toxin-based, and antibody-based drugs can significantly improve the biomedical efficiency of disease-specific therapy. The focus of this Special Issue of Biomolecules will be on the most recent advances related to novel peptides/proteins, antibodies, and toxins as forms of medicinal therapy. Recent advances in the discovery and development of these natural biomolecules for use in targeted therapy and immunotherapy against chronic diseases (e.g., cancer, diabetes, cardiovascular diseases, and rheumatoid arthritis) will be addressed. The discussion on using novel disease-specific proteins/peptides/toxins/antibodies along with currently available FDA-approved drugs as combinatorial treatments will also be encouraged in this context. Finally, an overview of some of the selected promising natural biomolecules that are potentially able to address the forthcoming challenges in this field will be included. Both research (in particular) and review articles proposing novelties or overviews, respectively, are welcome.
Format
  • Hardback
License
© by the authors
Keywords
DAPK1; SUMO; SENP; protein degradation; post-translational modification; amphibian Bowman-Birk inhibitor; Tat peptide; molecular cloning; antifungal; drug design; protease inhibitor; natural-based compound; anticancer therapy; lung cancer; survivin; apoptosis; STAT3; colorectal cancer; orientin; cell cycle arrest; Bcl-2 family proteins; apoptosis; Astragalus membranaceus; insulin; PI3K; AKT; PPARγ; PDX-1; Petasites japonicus; Asteraceae; lignan; anti-inflammation; NO; PGE2; iNOS; COX-2; molecular docking; peptides; kynurenines; binding affinity; μ-opioid receptor; pharmacophore; G-protein activation; fucoidan; PLGA; docetaxel; drug delivery system; anticancer therapy/cancer treatment; hIAPP; amyloidogenesis; insulin granules; endoplasmic reticulum; anionic lipids; F23R variant; β-sheet transitions; β-cell cytotoxicity; unfolded protein response; pomegranate; punicalagin; tannins; gingiva; fibroblasts; antioxidant; wound healing; branched-chain fatty acids; Conidiobolus heterosporus; peroxisome proliferator-activated receptor α; lipid metabolism; fatty acid oxidation; hepatocyte; n/a